U.S. markets closed

Pacific Biosciences of California, Inc. (PACB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
37.42+1.11 (+3.06%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close36.31
Open35.69
Bid37.10 x 1400
Ask37.60 x 800
Day's Range35.10 - 37.76
52 Week Range2.20 - 41.65
Volume3,505,213
Avg. Volume4,894,161
Market Cap7.006B
Beta (5Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-0.29
Earnings DateFeb 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why You Should Retain Pacific Biosciences (PACB) Stock Now
    Zacks

    Why You Should Retain Pacific Biosciences (PACB) Stock Now

    Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects.

  • Pacific Biosciences Reaches Our Price Target: Now What?
    TheStreet.com

    Pacific Biosciences Reaches Our Price Target: Now What?

    "This is another great stock," Jim Cramer told viewers of the Lightning Round segment of Mad Money Tuesday evening when asked about Pacific Biosciences of California Inc. . In the daily Japanese candlestick chart of PACB, below, we can see that the shares corrected modestly after our Dec. 9 review and subsequently rallied to the $39 price target. This chart shows that prices are above the rising 50-day moving average line and trade at more than three times the level of the rising 200-day moving average line.

  • Pacific Biosciences (PACB) Releases Preliminary Q4 Revenues
    Zacks

    Pacific Biosciences (PACB) Releases Preliminary Q4 Revenues

    Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320.